Literature DB >> 3260930

Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin.

M A Stene1, M Babajanians, S Bhuta, A J Cochran.   

Abstract

Melanomas are associated with a T-cell predominant infiltrate that may cause their regression. Langerhans cells (LC) are essential for initiation and maintenance of specific T-cell-mediate responses in the skin. Therefore, a change in this antigen-presenting LC population may alter the host response. To determine whether the LC population varies during the evolution of primary cutaneous melanoma 32 melanocytic lesions, nevi, and cutaneous melanomas were studied by quantitative immunohistology. The monoclonal antibody, Leu-6, and the avidin biotin complex immunoperoxidase method were used to identify LC. Compared with histologically normal melanoma-adjacent skin, epidermal LC were depleted above "deeply invasive" melanomas but were relatively unchanged above nevi, "early invasive" melanomas, and cutaneous metastatic melanoma nodules. Dermal LC were significantly increased around in situ and "early invasive" melanomas but not around "deeply invasive" melanomas or cutaneous metastatic nodules. Dermal LC are thus associated with early transformed melanocytes and may present neoantigens to T lymphocytes in situ or after LC maturation in the draining lymph node. Melanoma-associated LC decline in number as melanoma progresses.

Entities:  

Mesh:

Year:  1988        PMID: 3260930     DOI: 10.1111/1523-1747.ep12464142

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

Review 1.  How sunlight causes melanoma.

Authors:  Lilit Garibyan; David E Fisher
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

2.  Langerhans cells and melanocytes share similar morphologic features under in vivo reflectance confocal microscopy: a challenge for melanoma diagnosis.

Authors:  Pantea Hashemi; Melissa P Pulitzer; Alon Scope; Ivanka Kovalyshyn; Allan C Halpern; Ashfaq A Marghoob
Journal:  J Am Acad Dermatol       Date:  2011-07-28       Impact factor: 11.527

3.  Macrophages in melanocytic naevi.

Authors:  E B Bröcker; C Reckenfeld; H Hamm; D J Ruiter; C Sorg
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

4.  Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells.

Authors:  O Berthier-Vergnes; M Gaucherand; J Péguet-Navarro; J Plouet; J F Pageaux; D Schmitt; M J Staquet
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

5.  Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.

Authors:  G Pirtskhalaishvili; G V Shurin; C Esche; Q Cai; R R Salup; S N Bykovskaia; M T Lotze; M R Shurin
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

Review 6.  Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.

Authors:  Youra Kim; Derek R Clements; Andra M Sterea; Hyun Woo Jang; Shashi A Gujar; Patrick W K Lee
Journal:  Viruses       Date:  2015-12-09       Impact factor: 5.048

Review 7.  Strategies to Develop a Suitable Formulation for Inflammatory Skin Disease Treatment.

Authors:  Jiun-Wen Guo; Shiou-Hwa Jee
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

8.  Dendritic cells in the cancer microenvironment.

Authors:  Yang Ma; Galina V Shurin; Zhu Peiyuan; Michael R Shurin
Journal:  J Cancer       Date:  2012-12-15       Impact factor: 4.207

Review 9.  Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses.

Authors:  Björn E Clausen; Patrizia Stoitzner
Journal:  Front Immunol       Date:  2015-10-22       Impact factor: 7.561

10.  CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma.

Authors:  Grzegorz Dyduch; Katarzyna E Tyrak; Anna Glajcar; Joanna Szpor; Krzysztof Okoń
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.